HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Willemsen, R. A. Articles by Bolhuis, R. L. H. Search for Related Content PubMed PubMed Citation Articles by Willemsen, R. A. Articles by Bolhuis, R. L. H.

T Cell Retargeting with MHC Class I-Restricted Antibodies: The CD28 Costimulatory Domain Enhances Antigen-Specific Cytotoxicity and Cytokine Production¹

Ralph A. Willemsen^2,*, Cees Ronteltap^*, Patrick Chames, Reno Debets^* and Reinder L. H. Bolhuis^*

^* Laboratory of Tumor Immunology, Department of Medical Oncology, Erasmus Medisch Centrum Daniel den hoed, Rotterdam, The Netherlands; and Cellectis, Romainville, France

T cells require both primary and costimulatory signals for optimal activation. The primary Ag-specific signal is delivered by engagement of the TCR. The second Ag-independent costimulatory signal is mediated by engagement of the T cell surface costimulatory molecule CD28 with its target cell ligand B7. However, many tumor cells do not express these costimulatory molecules. We previously constructed phage display derived F_AB, G8, and Hyb3, Ab-based receptors with identical specificity but distinct affinities for HLA-A1/MAGE-A1, i.e., "TCR-like" specificity. These chimeric receptors comprised the FcRI- signaling element. We analyzed whether linking the CD28 costimulation structure to it ( + CD28) could affect the levels of MHC-restricted cytolysis and/or cytokine production. Human scFv-G8^POS T lymphocytes comprising the + CD28 vs the signaling element alone produced substantially more IL-2, TNF-, and IFN- in response to HLA-A1/MAGE-A1^POS melanoma cells. Also a drastic increase in cytolytic capacity of scFv-G8^POS T cells, equipped with + CD28 vs the -chain alone was observed.

This article has been cited by other articles:

				E. Yvon, M. Del Vecchio, B. Savoldo, V. Hoyos, A. Dutour, A. Anichini, G. Dotti, and M. K. Brenner Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells Clin. Cancer Res., September 15, 2009; 15(18): 5852 - 5860. [Abstract] [Full Text] [PDF]

				G. Stewart-Jones, A. Wadle, A. Hombach, E. Shenderov, G. Held, E. Fischer, S. Kleber, N. Nuber, F. Stenner-Liewen, S. Bauer, et al. Rational development of high-affinity T-cell receptor-like antibodies PNAS, April 7, 2009; 106(14): 5784 - 5788. [Abstract] [Full Text] [PDF]

				P. C.R. Emtage, A. S.Y. Lo, E. M. Gomes, D. L. Liu, R. M. Gonzalo-Daganzo, and R. P. Junghans Second-Generation Anti-Carcinoembryonic Antigen Designer T Cells Resist Activation-Induced Cell Death, Proliferate on Tumor Contact, Secrete Cytokines, and Exhibit Superior Antitumor Activity In vivo: A Preclinical Evaluation Clin. Cancer Res., December 15, 2008; 14(24): 8112 - 8122. [Abstract] [Full Text] [PDF]

				C. M. Kowolik, M. S. Topp, S. Gonzalez, T. Pfeiffer, S. Olivares, N. Gonzalez, D. D. Smith, S. J. Forman, M. C. Jensen, and L. J.N. Cooper CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances In vivo Persistence and Antitumor Efficacy of Adoptively Transferred T Cells. Cancer Res., November 15, 2006; 66(22): 10995 - 11004. [Abstract] [Full Text] [PDF]